GC Pharma affiliate Artiva Biotheraputics announced on the 12th that it has signed a contract with MSD to expand the development of natural killing (NK) cell therapy. Artiva was established in 2019 by GC CELL and GC LABTECH in San Diego, USA. Under the contract, the two companies will promote joint research on anticancer drugs that combine NK cell therapy AB-101 under development with Tri-Specific NK-Cell Engagers owned by MSD.

In particular, this contract was signed by Artiva in January last year after exporting platform technology worth KRW 2 trillion to MSD with GCELL. Artiva is already jointly developing three "CAR-NK cell treatments" for MSD and solid cancer treatment.

The triple-spe